MDMB-4en-PINACA

The clinical evidence is unusually good for a compound of this kind, because two hospital systems screened for it routinely rather than waiting for suspicion.

The Birmingham series covers 202 presentations over four years with analytical confirmation, and is the backbone of what is known ^[3]. A separate series of seven vaping cases had a median age of 17, with psychotic features in 57 percent ^[4]. The Bordeaux cases are the cleanest evidence of all, because those thirteen people believed they had smoked cannabis, which removes most of the confounding that dogs this literature ^[5].

⚠️ Exposure is frequently involuntary, which changes who the warning is for. Of 1,142 European samples sold as cannabis, 270 contained this compound ^[7]. It has also been found in vapes collected from schools and in bags sold as heroin.

Detection is genuinely difficult and the reasons are specific. Immunoassay screens target metabolites of older, structurally unrelated compounds at cutoffs above the concentrations that actually occur. Under 7.5 percent of the parent compound survives an hour in human liver preparations ^[14]. And ⚠️ its main metabolite is not its own: ester hydrolysis of this compound and amide hydrolysis of the closely related ADB-4en-PINACA converge on the identical acid, so the usual biomarker cannot say which was taken ^[13][12]. The one specific marker is also the weakest, at under five percent of metabolite abundance.

⚠️ One expectation to discard: the parent compound was detectable in a survivor's blood for eleven days, against a stated usual window of a few hours. A late negative result does not exclude exposure.

⚠️ Three figures in circulation are omitted here because they could not be sourced. A widely repeated efficacy figure of 654 percent of THC traces to an introduction citing three papers, none of which contains it. A set of per-case post-mortem concentrations is attributed to two regulatory documents, both of which were searched and contain no blood concentrations at all. And no single death total is given, because the two authoritative sources disagree.

⚠️ A BLOOD CONCENTRATION CARRIES NO INTERPRETIVE VALUE FOR THIS COMPOUND, and this is the most important line on the page. The only fully quantified fatality in the peer-reviewed literature measured 7.2 ng/mL in peripheral blood, in a healthy 26-year-old who collapsed at home, with a second synthetic cannabinoid also present and no anatomical cause of death at autopsy ^[2]. A 21-year-old who survived after nineteen days of sedation was still at 3.203 ng/mL on day three, so his peak was plausibly above the fatal number. There is no established toxic threshold and no lethal one, and the authors of the fatal case say the relationship between concentration and effect is unpredictable, with deaths at relatively low levels in young healthy people.

What the clinical record shows, across 202 emergency presentations from 163 patients ^[3]: reduced level of consciousness in 81.2 percent, agitation in 49 percent, seizures in 30.2 percent, low blood pressure in 22.3 percent, raised lactate in 47 percent and raised muscle-breakdown markers in 38.1 percent. Four people died. Nearly a third were homeless. ⚠️ In the 15 cases where it was the only substance found, the picture matched the whole group, which is what makes the attribution credible.

⚠️ The seizure signal is the most reproducible severe effect. It held at 30 percent in the largest series, in 5 of 13 people who believed they were smoking cannabis ^[5], and in the sole-agent cases.

Cardiovascular effects are reported for the class, but the compound-specific evidence is thin and should be described that way: heart rate was not collected as a variable in the largest series at all, and where hypotension appeared in 22 percent, high blood pressure appeared in about 2 percent.

Respiratory failure is a class finding ^[15], and worth stating carefully: that study confirmed 25 percent respiratory failure across synthetic cannabinoid overdoses against 4.2 percent for other drugs, but only one of its 29 confirmed cases was this compound.

⚠️ There is no antidote and no reversal agent. Management is supportive. A search of the indexed literature for any reversal strategy in this class returns nothing.

⚠️ A NEGATIVE DRUG SCREEN DOES NOT RULE IT OUT. In a series of jail deaths, expanded routine toxicology panels detected no illegal drugs at all, and only analysis specifically targeting synthetic cannabinoids found it ^[6].

The compound was first detected in Europe in 2017 and formally notified to the European early-warning system in 2018, after a test purchase of nearly eight grams sold online under a different code name entirely. It spread quickly: European police seizures went from one in 2017 to 388 in 2020, and United States forensic laboratory reports peaked above 5,600 in 2020. Between roughly 2020 and 2022 it was among the most frequently detected synthetic cannabinoids in the world, accounting for 42 percent of synthetic-cannabinoid toxicology cases reported to the United Nations early-warning system by late 2022. It did not hold that position: European monitoring records that ADB-BUTINACA overtook it during 2021, and a Chinese generic ban in mid-2021 collapsed the supply of powder into Europe. It was placed under international control in 2021, controlled across the European Union the same year, and permanently scheduled in the United States in 2026. In the United Kingdom it was never a legal high at all: the generic definition covering this class, written in 2016, already captured it before it appeared.